Heart failure is an increasingly recognized complication in chronic diabetes that may be caused by a number of processes including direct effects of hyperglycemia on the heart muscle. So-called diabetic cardiomyopathy may affect up to 20% of people with chronic diabetes and represents a unique target for treatment.   In this interview, James Januzzi, MD, FACC, and Alison L. Bailey, MD FACC discuss the primary results from the ARISE-HF study: Selective Aldose Reductase Inhibitor For...

It's becoming increasingly evident that alongside top-notch clinical expertise, the CV specialist of the future must be surrounded by a multi-talented, diverse team to provide optimal patient care. In addition, it is crucial that the clinician and CV organization engage in non-clinical competencies to enhance value for patients, the healthcare system, and society. MedAxiom and ACC collaborate synergistically toward achieving these goals.  In this interview, Jerry Blackwell MD, MBA, FACC...

Patients with acute myocardial infarction are at a high risk of heart failure and death. Despite advances in care and reduction in the rate of recurrent myocardial infarctions, the risk for heart failure continues to be unacceptably high. No intervention in 2 decades has been shown to improve this risk.   In this interview, Javed Butler, MD, MPH, MBA, and Sun Moon Kim, MD, FACC, discuss the results of the EMPACT-MI trial. 

About half of patients with chronic heart failure have an ejection fraction >40%. Therapy for patients in this group has been challenging until recently; few therapies have been effective in improving clinical outcomes in this population. Recently, data from several clinical trials of SGLT2 inhibitors, mineralocorticoid receptor antagonists (MRA), Angiotensin-receptor neprilysin inhibitors (ARNI), and GLP-1 receptor agonists, however, have offered potential for targeted therapy in this...

Aortic valve disease is often identified too late before clinicans can provide meaningful prevention.  Identifying aortic valve calcium opens the door for potential prevention of progression: a phenotype researchers could build randomized controlled trials around.     In this interview, Richard A. Chazal MD, MACC and Michael J. Blaha, MD, MPH discuss Prevalence of Aortic Valve Calcium and the Long-Term Risk of Incident Severe Aortic Stenosis.     Subscribe on Apple...

After a heart attack, it is important to lower cholesterol levels to prevent future heart attacks. Monitoring cholesterol levels on treatment is just as important as monitoring blood pressure levels on treatment to make sure that the medicines are having the desired effect.  In this interview, C. Noel Bairey Merz, MD, FACC, and Vera Bittner, MD, MSPH, FACC, discuss Low-Density Lipoprotein Cholesterol Testing Following MI Hospitalization Among Medicare Beneficiaries.   Subscribe on...

This episode covers a review on disparities in cardiovascular perioperative health care. The writers propose actionable solutions utilizing multidisciplinary perspectives from cardiology, cardiac surgery, cardiothoracic anesthesiology, critical care, medical ethics, and health disparity experts.  In this interview, Adam J. Milam, MD, PhD, and Clyde W.Yancy, MD, MSc, MACC, discuss the JACC State-of-the-Art Review: Racial and Ethnic Disparities in Perioperative Health Care Among Patients...

Cardiac imaging is increasingly used in the workup of coronary artery disease, with growth greatest for CCTA and with falling use of SPECT. Because of the low cost of computed tomography, this growing use of imaging has had only a small impact on cost of provision of diagnostic imaging in this population.  In this interview, Jonathan R. Weir-McCall, PhD, and Christopher M. Kramer, MD, FACC, discuss From JACC: National Trends in Coronary Artery Disease Imaging: Associations With Health...

In this interview, José A. Joglar, MD, FACC, and Joseph E. Marine MD, MBA, FACC, discuss the top takeaways from the latest atrial fibrillation (AFib) guideline, which provides new and updated recommendations for preventing and optimally managing AFib.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

A study provides new data for patients with genetic heart disease (GHD) and exercise recommendations. For decades, those with GHD were excluded from exercise and sports participation. This has led to poor exercise tolerance, increased risk for CAD and poor outcomes in this group related to reduced fitness.  This study helps frame that those with GHD are unique and as a result, require an individualized approach to care. After expert consultation, patients with GHD can often be safe to...

Continuous cardiac monitoring detects brief, asymptomatic, heart rhythm abnormalities in one-third of older individuals and these symptoms are associated with an increased risk of stroke.  The ARTESiA trial clearly demonstrates that use of the blood thinner apixaban reduces patient risk of stroke compared to treatment with aspirin, but is associated with an increased risk of bleeding.  In this interview, Jeff S. Healey, MD, and Thomas F. Deering MD, FACC, discuss AHA Late-Breaker:...

The 2023 guideline provides an evidenced-based and patient-centered approach to management of patients with chronic coronary disease, considering social determinants of health and incorporating the principles of shared decision-making and team-based care. In this interview, Kristin Newby, MD, FACC, and Nanette Kass Wenger MD, MACC, discuss Behind the ACC 2023 Guideline for Chronic CAD: Conversations and Controversies.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to...

To improve our understanding of the basic principles in the treatment and management of patients with chronic heart disease, in this interview, Salim S. Virani, MD, PhD, FACC, and Roger S. Blumenthal, MD, FACC, discuss top takeaways from the ACC 2023 Guideline for Chronic CAD.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

Patients with worsening heart failure are at an extraordinarily high risk for mortality and readmission. Early identification and optimal management of these patients can significantly improve patient outcomes. Several clinical trials in these patients have shown benefit with various therapies.  In this interview, Javed Butler, MD, MPH, MBA, FACC, and Matthew Martinez, MD, FACC, discuss Management of Worsening Heart Failure with Reduced Ejection Fraction.   Subscribe on Apple Podcasts...

The SELECT trial extends findings from previous trials, which demonstrated cardiovascular benefit in diabetes mellitus (DM), to those without DM. In this interview, Abraham Lincoff, MD, FACC, and Glenn A. Hirsch MD, MHS, FACC, discuss AHA Late-Breaker: SELECT – Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this review, authors discuss how multimodality imaging can help to evaluate the left ventricular remodeling response and improve risk stratification in patients with moderate aortic stenosis.   In this interview, Jeroen J Bax, MD, PhD, FACC, and Matt Cavender, MD, MPH, FACC, discuss JACC review, Managing Patients With Moderate Aortic Stenosis.  Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Andrew Kates, MD, FACC, and Alison L. Bailey, MD, FACC, discuss the top takeaways in general cardiology from 2023 including ARAMIS, ORBITA-2, and STOP-CA trials.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

While we know that statin treatment reduces the risk of stroke, heart attack and heart deaths in people at moderate-to-high risk, or with high cholesterol, in REPRIEVE statins decreased the risk in those at low-to-moderate risk, and with 'normal' cholesterol levels who would not usually be considered candidates for treatment.   In this interview, Pamela S. Douglas, MD, MACC, and Roger S. Blumenthal MD, FACC, discuss Pitavastatin to Prevent Cardiovascular Disease in HIV Infection.  ...

In this interview, Dhanunjaya “DJ” Lakkireddy, MBBS, FACC, and Alison L. Bailey, MD, FACC discuss the top takeaways from 2023 in cardiac electrophysiology including AF and the latest guidelines and ARTESIA and MONITOR-AF studies.    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Noel Bairey Merz, MD, FACC, and Alison L. Bailey, MD, FACC discuss the top takeaways from 2023 in Preventive Cardiology including the CLEAR-Outcomes, REPRIEVE, and SELECT trials.     Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL  

In this interview, Clyde Yancy MD, MSc, FACC, and Alison L. Bailey MD, FACC, discuss the Top Takeaways from 2023 in Heart Failure. Dr. Yancy discusses trials including STEP-HFpEF, SELCT and DELIVER.    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Christopher M. Kramer MD, FACC, and Alison L. Bailey MD FACC, discuss the Top Takeaways from 2023 in CV Imaging. Dr. Kramer discusses the PRECISE trial, AI evolution in imaging and more.    Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

In this interview, Deepak Bhatt, MD, FACC, and Alison L. Bailey, MD FACC, discuss Top Takeaways from 2023 in Interventional Cardiology. Dr. Bhatt discusses trials including FIRE, MULTISTARS, and TRILUMINATE.   Subscribe on Apple Podcasts | Subscribe on Google Play | Subscribe to ACCEL 

ORBITA-2 was designed to test whether stents reduce angina more than a placebo procedure in patients with single or multivessel disease on little or no antianginal medication at 12 weeks of follow up. In this interview, Christopher Rajkumar, MD, Rasha Al-Lamee, MD, and William E. Boden MD, FACC, discuss AHA Late-Breaker: Percutaneous Coronary Intervention for Stable Angina (ORBITA-2): A Randomized, Placebo-Controlled Trial.  Subscribe on Apple Podcasts | Subscribe on Google Play | ...